In allogeneic hematopoietic cell transplantation (HCT), donor T cellmediated graft versus host leukemia (GVL) and graft versus autoimmune (GVA) activity play critical roles in treatment of hematological malignancies and refractory autoimmune diseases. However, graft versus host disease (GVHD), which sometimes can be fatal, remains a major obstacle in classical HCT, where recipients are conditioned with total body irradiation or high-dose chemotherapy. We previously reported that anti-CD3 conditioning allows donor CD8 ؉ T cells to facilitate engraftment and mediate GVL without causing GVHD. However, the clinical application of this radiation-free and GVHD preventative conditioning regimen is hindered by the cytokine storm syndrome triggered by anti-CD3 and the high-dose donor bone marrow ( anti-CD3 mAb ͉ graft versus host disease ͉ hematopoietic cell transplantation ͉ systemic lupus erythematosus ͉ suberoylanilide hydroxamic acid
anti-CD3 mAb ͉ graft versus host disease ͉ hematopoietic cell transplantation ͉ systemic lupus erythematosus ͉ suberoylanilide hydroxamic acid A llogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies and refractory autoimmune diseases such as systemic lupus erythematosus (SLE) (1) (2) (3) . However, in classical HCT, recipients are usually conditioned with total body irradiation (TBI) and/or high-dose chemotherapy. The toxicity of conditioning, even with reduced intensity, and the potential for graft versus host disease (GVHD) are preventing the application of allogeneic HCT to the treatment of refractory autoimmune diseases, although it is considered justified for the treatment of life-threatening hematological malignancies (1) (2) (3) .
It has been demonstrated that TBI and high-dose chemotherapy conditioning play a critical role in initiating GVHD (4) . The conditioning procedures cause tissue damage, release of proinflammatory cytokines and chemokines, and activation of host antigen-presenting cells (APCs), resulting in a proinflammatory cascade and donor alloreactive T cell infiltration of GVHD target tissues (5) (6) (7) . Therefore, we and others have been searching for a radiation-free and GVHD-preventive conditioning regimen for allogeneic HCT. It was reported that transplantation of a large dose of donor bone marrow (BM) cells and administration of costimulatory blockade (i.e., anti-CD40L) induced mixed chimerism in nonautoimmune mice (8) , but this regimen has not been shown to work in autoimmune mice.
We recently reported that infusion of donor CD8 ϩ T or CD4 ϩ T-depleted spleen cells and BM cells induced chimerism without GVHD in nonautoimmune and autoimmune NOD mice (9) (10) (11) .
The mechanisms of GVHD prevention in the anti-CD3-conditioned recipients include confining donor CD8 ϩ T cells to host lymphohematological tissues and tolerizing the alloreactive T cells (10) . The anti-CD3-conditioning regimen allows donor CD8 ϩ T cells to mediate graft versus host leukemia (GVL) activity and graft versus autoimmune (GVA) activity without causing GVHD (9) (10) (11) . In addition, the chimeric NOD recipients with chimerism established by anti-CD3 conditioning showed regeneration of islet ␤-cells and reversal of diabetes (11) . Therefore, the anti-CD3-conditioning regimen has the potential to promote allogeneic HCT for treating autoimmune diseases. However, anti-CD3 conditioning often causes a cytokine storm syndrome, which includes hypothermia and hypoglycemia. The cytokine storm syndrome and the high-dose donor BM cells required for the induction of chimerism hamper the clinical application of this anti-CD3-based conditioning regimen. Chromatin remodeling by acetylation or deacetylation of histones play an critical role in the regulation of gene expression (12, 13) . Histone acetylation is controlled by two classes of enzymes: histone acetyltransferases (HATs) add acetyl groups to lysine residues, whereas histone deacetylases (HDACs) remove the acetyl groups (13) . Acetylation of histones relaxes chromatin structure, allowing the binding of transcription factors and promoting transcription. In contrast, deacetylation of histones condenses chromatin structure and represses gene transcription (12, 13) . Inhibiting the deacetylation of histones results in hyperacetylation and modifies gene expression either positively or negatively in a cell type-specific manner (13) .
Suberoylanilide hydroxamic acid (SAHA), also known as vorinostat, contains a hydroxamic acid moiety that binds to the zinc-containing pocket in the catalytic site of the HDAC 6 and thus causes their reversible inhibition (14) . It has been reported that SAHA selectively increases the expression of many genes in tumor cells, causing them to undergo cell-cycle arrest and apoptosis (15) . Although micromolar concentrations of SAHA are required for anti-tumor effects, nanomolar concentrations of SAHA can reduce the secretion of inflammatory cytokines such as TNF-␣, IFN-␥, IL-1␤, and IL-12 by nonmalignant cells (16) . It was reported that administration of low-dose SAHA reduced serum levels of inflammatory cytokines and ameliorated GVHD without inhibiting donor T cell function and their GVL activity (17, 18) .
In the current study, we also found that high-concentration SAHA augmented apoptosis and low-concentration SAHA inhibited the proliferative and cytotoxic activity of the anti-CD3-activated T cells. Administration of low-dose SAHA during anti-CD3 conditioning ameliorated cytokine storm syndrome and augmented the induction of chimerism without causing GVHD. In addition, conditioning with anti-CD3 and SAHA allowed induction of complete chimerism without causing GVHD, which ''cured'' systemic lupus in NZB/W F1 mice with severe glomerulonephritis. This radiation-free and GVHDpreventative conditioning regimen has great potential for clinical application.
Results

SAHA Augmented Apoptosis and Inhibited Proliferation of Anti-CD3-
Activated T Cells in a Dose-Dependent Manner. SAHA was shown to mediate apoptosis of growing tumor cells (15) and inhibit proliferation of autoreactive T cells (19) . Therefore, we tested the effect of SAHA on T cells that were activated by anti-CD3 mAb. BALB/c spleen cells were stimulated with plate-bound anti-CD3 in the culture medium with titrated concentration of SAHA (0.5-4 M) or solvent DMSO for 72 h. We found that SAHA augmented T cell apoptosis in a dose-dependent manner. Although 0.5 M SAHA showed little augmentation of T cell apoptosis compared with cells stimulated with anti-CD3 alone, 1 M SAHA augmented the apoptosis by Ϸ2-fold; 2 M SAHA augmented the apoptosis by Ϸ3-fold; and 4 M SAHA led to apoptosis of nearly all T cells (P Ͻ 0.01, Fig. 1A ). Cells cultured with medium alone and cells cultured with SAHA alone showed little apoptosis (data not shown). It was of interest that, although 0.5 M SAHA did not significantly change the apoptosis or survival rate of the anti-CD3-activated T cells ( Fig. 1 A and B) , it inhibited the proliferation of the T cells by 2-fold (P Ͻ 0.01, Fig. 1C ). Although 40% of the residual T cells in the culture of 1 M SAHA were annexin V Ϫ live cells, they showed no proliferation at all (P Ͻ 0.01, Fig. 1C ). In addition, consistent with the previous reports (17, 18) , 0.5 M SAHA showed no inhibition of the donor T cells stimulated with allo-APCs, but 1 M SAHA markedly inhibited the T cell proliferation (Fig. 1D) . These results indicate that high concentrations (Ͼ1 M) of SAHA augment apoptosis and low concentrations (Ͻ1 M) of SAHA inhibit the proliferation of the anti-CD3 activated T cells.
Administration of Low-Dose SAHA Reduced Cytokine Storm Triggered by Anti-CD3. One of the side effects of anti-CD3 conditioning was the cytokine storm triggered by anti-CD3 activation of T cells. The elevated levels of TNF-␣ during the cytokine storm caused hypothermia, and the mice appeared to be inactive (20) . Next, we tested whether SAHA could reduce cytokine production triggered by anti-CD3. First, BALB/c spleen cells (0.5 ϫ 10 6 ) were stimulated with plate-bound anti-CD3 in culture medium with 0.5 or 1 M SAHA. Supernatants were harvested 24, 48, and 72 h after culture, and IL-2, IFN-␥, TNF-␣, and IL-6 concentrations were measured with ELISA. We observed that, after anti-CD3-stimulation, IL-2 concentration peaked at 48 h after culture, and IFN-␥, TNF-␣, and IL-6 all peaked at 72 h after culture. Compared with the culture with anti-CD3 stimulation only, addition of 0.5 M SAHA to the culture reduced cytokine production significantly at all time points (P Ͻ 0.05, Fig. 2A ), and addition of 1 M SAHA to the culture made all four cytokines nearly undetectable (P Ͻ 0.01, Fig. 2 A) .
Second, old BALB/c mice (Ͼ16 weeks) were injected with anti-CD3 (5 g/g) alone or anti-CD3 and SAHA at 40, 100, or 200 g/g. Sera were harvested kinetically at 0.5, 1, 2, 4, 8, and 24 h after injection for the measurement of cytokines. The mice were also measured for body temperature at the same time. We observed that, after injection of anti-CD3 alone, serum IL-2 levels peaked at 1 h after injection; serum IFN-␥ levels peaked at 8 h; serum TNF-␣ and IL-6 levels peaked at 2 h; and all of the serum cytokine levels fell back to background levels 24 h after injection (Fig. 2B) . Interestingly, the mice started to look sick 24 h after injection and appeared to be most inactive 48 h after injection, and then they recovered and looked fairly normal again 96 h after injection. The body temperature of the mice reached its lowest level 48 h after injection and then recovered to nearly normal 96 h after injection (Fig. 2C) .
However, coinjection of SAHA at a dose of 40 g/g reduced serum levels of IL-2, IFN-␥, TNF-␣, and IL-6 by Ͼ2-fold at the peak time points compared with that of the mice injected with anti-CD3 alone (P Ͻ 0.01, Fig. 2B ). The coinjection of SAHA also significantly improved hypothermia (P Ͻ 0.01, Fig. 2C ), and the treated mice appeared much more active. Coinjection of SAHA at a dose of 100 g/g resulted in similar serum cytokine reduction and improvement in hypothermia compared with the mice coinjected with SAHA at 40 g/g (data not shown). However, coinjection of SAHA at a dose of 200 g/g caused the mice to develop severe diarrhea, and 30% of the mice died 5 days after anti-CD3 conditioning, although they all had similar reductions in serum cytokine levels compared with the mice coinjected with SAHA at 40 g/g (data not shown). Together, our results indicate that administration of a low dose (Յ100 g/g) of SAHA ameliorates cytokine storm syndrome triggered by mitogenic anti-CD3.
Coinjection of Low-Dose SAHA Augmented Induction of Chimerism in
Old BALB/c Recipients Conditioned with Anti-CD3. We observed that conditioning with anti-CD3 alone was not sufficient for induc- tion of chimerism in old (Ͼ12-week-old) recipients, although it was sufficient in young (Ͻ8-week-old) recipients (11) . Next, we tested whether the coinjection of low-dose SAHA could augment induction of chimerism in old recipients. Accordingly, old (Ͼ16-week-old) BALB/c mice were conditioned with anti-CD3 alone or with a combination of anti-CD3 and SAHA (40 g/g). Nine days after conditioning, mice were injected with BM (2 ϫ 10 6 /g, Ϸ50 ϫ 10 6 per mouse) and CD4 ϩ T-depleted spleen cells (4 ϫ 10 6 /g) from C57BL/6 donors. The recipients were monitored for clinical signs of GVHD and checked for chimerism 8 weeks after HCT. We found that 0/12 of the recipients conditioned with anti-CD3 alone developed chimerism, but 12/12 of the recipients conditioned with anti-CD3 and SAHA developed complete chimerism, in which almost all of the T, B, macrophage, and granulocyte cells were donor type (Table 1 and Fig.  3A) . We observed no clinical signs of GVHD in the chimeric recipients, and their body weight change was the same as that of the nonchimeric mice given conditioning only (Fig. 3B) . These results indicate that SAHA can augment the induction of chimerism without augmenting the induction of GVHD when coinjected with anti-CD3 for conditioning allogeneic recipients.
Next, we explored the mechanisms whereby SAHA augmented engraftment when used with anti-CD3 in the conditioning of recipients. Because host T cells play a major role in graft rejection, we focused on the effect of SAHA on host T cells. We found that coinjection of low-dose (40 or 100 g/g) SAHA neither significantly increased the apoptosis of host T cells nor reduced the yield of residual live T cells in the spleen of treated mice (Fig. 3C) . Because low-concentration SAHA inhibited proliferation of anti-CD3 activated T cells, although it did not augment apoptosis of the T cells (Fig. 1) , we compared the proliferative capacity of T cells from the BALB/c recipients conditioned with anti-CD3 alone or anti-CD3 and SAHA in response to stimulation by C57BL/6 donor dendritic cells. We found that the proliferation of the T cells from the former was 2-fold more compared with the latter (P Ͻ 0.01, Fig. 3D ). Furthermore, we compared the cytotoxic activity of the residual host T cells in recipients conditioned with anti-CD3 alone or anti-CD3 plus SAHA 5 days after HCT by injection of spleen cells from naïve donor and host mice. We found that residual host T cells in anti-CD3-conditioned recipients had stronger cytotoxic activity compared with those in the recipients conditioned with anti-CD3 and SAHA, so that the ratio of the residual CD45.1 ϩ donor-type targets versus carboxyfluoroscein succinimidyl ester (CFSE)-labeled host-type targets in the recipients conditioned with anti-CD3 was 2-fold lower than that in the recipients conditioned with anti-CD3 plus SAHA (P Ͻ 0.01, Fig.  3 E and F) . Together, augmentation of engraftment by conditioning with low-dose SAHA and anti-CD3 is at least in part via inhibition of the rejecting function of the residual host T cells.
Conditioning with Anti-CD3 and Low-Dose SAHA Allowed Induction of Complete Chimerism That Reversed Overt Lupus. Sorted allogeneic stem cells recently have been shown to establish mixed chimerism in sublethally irradiated NZB/W F1 recipients and reverse overt lupus (21) . However, 50% of the chimeric recipients continued to have high levels of serum autoantibodies, and Ϸ30% of the chimeric recipients continued to have proteinuria and eventually died of lupus (21) . This observation indicates that the pathogenic memory T and B cells continue to exist in the lupus recipients with mixed chimerism and continue to mediate lupus, and induction of complete chimerism may be required for the cure of lupus.
We tested whether conditioning with anti-CD3 and SAHA could allow induction of complete chimerism without GVHD in old NZB/W F1 mice with severe glomerulonephritis and proteinuria. First, we observed that one injection of anti-CD3 with multiple injections of low-dose SAHA (40 g/g) was not sufficient for induction of chimerism in old NZB/W F1 mice with severe proteinuria (data not shown), which might be attributable to the loss of antibody and SAHA in urine, which could have led to the insufficient depletion of host T cells. Therefore, we repeated the injection of anti-CD3 and SAHA 5 days after the first injection. Five days after the second injection, the mice were infused with the same dose of donor BM cells (2 ϫ 10 6 /g) and CD4
ϩ T-depleted spleen cells (4 ϫ 10 6 /g) as used for the old BALB/c mice. We found that, although none (0/10) of the recipients conditioned with anti-CD3 alone developed chimerism, all (10/10) of the recipients conditioned with anti-CD3 and SAHA developed complete chimerism (Table 1 and Fig. 4A ). In addition, the chimeric recipients showed no clinical signs of GVHD over a 180-day period after HCT, and the recipients showed a steady body weight increase as they aged. In contrast, the nonchimeric recipients conditioned with anti-CD3 alone showed severe body weight loss caused by the progression of lupus (Fig. 4B) . We also longitudinally monitored the proteinuria, serum autoantibody levels, and survival of the lupus mice with or without chimerism. We found that the nonchimeric recipients conditioned with anti-CD3 alone temporarily reversed lupus in Ϸ50% of the mice, but they all showed severe proteinuria again 60 days after treatment and all died 120 days after treatment (Fig. 4 C and D) . In contrast, all of the chimeric recipients became proteinuria-free Ϸ50 days after HCT and all survived for Ͼ180 days after HCT (Fig. 4 C and D) . The serum anti-dsDNA levels of the chimeric recipients gradually decreased and became almost undetectable by 60 days after HCT (Fig. 4E) . The histopathology of the kidneys of the chimeric recipients were compared with that of the lupus mice before HCT. We found that, although the glomeruli of the untreated lupus mice appeared swollen and had severe IgG deposition, the glomeruli of the chimeric recipients appeared to be normal and had very little IgG deposition (Fig. 4F) . These results indicate that conditioning with anti-CD3 and SAHA allows donor CD8 ϩ T cells to eliminate host memory pathogenic T cells and autoantibodysecreting B cells without causing GVHD and to cure lupus glomerulonephritis. 
Discussion
We have demonstrated that low-dose SAHA reduced serum cytokine levels and ameliorated the cytokine storm syndrome triggered by anti-CD3 during conditioning; the low-dose SAHA also reduced the proliferative and cytotoxic activity of the residual host T cells, resulting in augmentation of donor hematopoietic cell engraftment without causing GVHD. In addition, we demonstrated that conditioning with SAHA and anti-CD3 allowed induction of complete chimerism and cure of severe lupus glomerulonephritis.
We observed that low-dose SAHA reduced in vitro and in vivo cytokine production (IL-2, IFN-␥, TNF-␣, and IL-6) triggered by mitogenic anti-CD3. It is not yet clear how SAHA inhibits the cytokine cascade triggered by anti-CD3 activation of T cells. It is likely that SAHA inhibits the transcription and translation of IL-2 in T cells and subsequently inhibits cytokine secretion by T cells and other cells such as macrophages. It was reported that an HDAC inhibitor (trichostatin A) represses IL-2 gene expression in anti-CD3 activated T cells (22) . Low-dose SAHA treatment resulted in increased acetylation of histone H3 and decreased mRNA levels of IFN-␥ and TNF-␣ in activated spleen cells (17) . SAHA treatment also inhibited phosphorylation of STAT1 and STAT3 in response to LPS and alloactivation in vitro (18) , and STAT1 and STAT3 play a critical role in the production of proinflammtory cytokines such as IFN-␥ and IL-17 (23, 24) . Administration of low-dose SAHA also ameliorated cytokine storm symptoms such as hypothermia triggered by anti-CD3. This finding might result from the marked reduction in the serum levels of TNF-␣ after administration of SAHA. It was reported previously that cytokine storm syndrome caused by injection of mitogenic anti-CD3 was ameliorated by neutralizing TNF-␣ (20) .
We observed that SAHA augmented induction of chimerism when used with anti-CD3 for conditioning of allogeneic recipients, which was consistent with our observation that highconcentration SAHA augmented the apoptosis and lowconcentration SAHA reduced the proliferative and cytotoxic activity of T cells activated by anti-CD3. Thus, the residual T cells in the recipients conditioned with anti-CD3 and low-dose SAHA had a reduced capacity to reject the donor cells. It is not yet clear how SAHA renders the anti-CD3-activated T cells apoptotic or less proliferative/cytotoxic. High concentrations of SAHA have been shown to induce tumor cell apoptosis by activating extrinsic Fas-FasL and TNF␣R-TNF-␣ apoptotic pathways (15) and cytochrome-caspase-9 intrinsic pathways (15); low concentration of SAHA predominantly induced cell-cycle arrest at G 1 phase in both normal and transformed cells (15) . In addition, we observed that SAHA markedly reduced the IL-2 production of anti-CD3 activated T cells, which may contribute to the reduction of T cell proliferation because IL-2 plays a critical role in T cell proliferation. Therefore, SAHA can augment depletion or inhibition of the anti-CD3-activated host T cells, resulting in facilitation of donor hematopoietic cell engraftment. Donor T cells usually induced GVHD in recipients conditioned with chemotherapy (1, 25) . However, we observed no clinical signs of GVHD in the recipients conditioned with anti-CD3 and SAHA after infusion of a high dose of CD4 ϩ T-depleted spleen cells. The GVHD prevention mechanisms in recipients conditioned with anti-CD3 alone, which include confining of donor T cells to host lymphohematological tissues and tolerizing the residual alloreactive donor T cells, was reported in our previous publication (10) . It is not surprising that the addition of SAHA to the anti-CD3-conditioning regimen did not lead to induction of GVHD, even though SAHA is a chemoreagent, because unlike traditional chemoreagents that cause host tissue damage and release of proinflammatory cytokines and chemokines (1, 4) , SAHA inhibits the tissue release of the proinflammatory cytokines and chemokines (16) (17) (18) . In addition, HDAC inhibitors similar to SAHA have been shown to augment the generation and function of FoxP3 ϩ regulatory T (Treg) cells (26) and modulate APC function to down regulate Th1 differentiation (27) . Treg cells were shown to prevent GVHD (28) , and Th1 cells were shown to mediate GVHD (1) .
Induction of mixed chimerism with sorted donor stem cells was able to ameliorate systemic lupus but not able to cure the disease (21) , indicating that GVA activity mediated by donor T cells may be required. However, GVA activity is usually associated with GVHD in recipients conditioned with TBI or high-dose chemotherapy (2, 3). In our current study, NZB/W F1 mice with severe glomerularnephritis and proteinuria were conditioned with SAHA and anti-CD3 and were induced to develop complete chimerism with no clinical signs of GVHD. The chimeric recipients showed gradual disappearance of serum autoantibodies, proteinuria, and glomerularnephritis. These results indicate that conditioning with anti-CD3 and SAHA allows donor CD8 ϩ T cells to mediate GVA activity without causing GVHD.
In conclusion, addition of a HDAC inhibitor such as SAHA to the anti-CD3-based conditioning regimen ameliorates the cytokine storm syndrome triggered by the mitogenic anti-CD3 and reduces the required donor BM dose for induction of chimerism but does not cause GVHD. This is a demonstration that an anti-tumor chemoreagent can be used for conditioning of allogeneic recipients without induction of GVHD. This radiationfree and GVHD-preventive conditioning regimen may promote the application of allogeneic HCT for treating refractory autoimmune disease in addition to the treatment of hematological malignancies.
Materials and Methods
Mice. C57BL/6 (H-2 b , CD45.2), congenic C57BL/6 (H-2 b , CD45.1), BALB/c (H-2 d ),and female NZB/W F1 (H-2 d/z ) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All animals were maintained in a pathogen-free room at City of Hope Animal Research Facilities (Duarte, CA). Animal use protocols were approved by the institutional review committee.
Flow Cytometric Analysis and Cell Sorting. The following anti-mouse mAbs were purchased from BD Biosciences PharMingen (San Diego, CA), eBioscience (San Diego, CA), and R&D Systems (Minneapolis, MN): TCR (H57-597), CD4 (RM4 -5), CD8 (53-6.7), B220 (RA3-6B2), CD11b/Mac-1 (M1/70), Gr-1 (RB6 -8C5), CD45.1(A20), H-2 b (AF6 -88.5), and H-2 d (34 -2-12). FACS was performed with a four-laser MoFlo Immunocytometry System (Dako Cytomation, Fort Collins, CO), and data were analyzed with FlowJo software (Tree Star, San Carlos, CA), as previously described (9 -11) . The apoptosis measuring kit (antiannexin V Ab) was purchased from BD PharMingen. CD4 Ϫ -SPL cells from donor spleen were negatively selected with anti-CD4-FITC and anti-FITC micromagnetic beads purchased from Miltenyi Biotec (Auburn,CA), as previously described (9 -11).
Chemoreagents. SAHA (vorinostat) was provided by Aton Merck Pharmaceutical and the National Cancer Institute. SAHA was dissolved in DMSO at 1 M and aliquots were kept at Ϫ20°C. For in vitro assays, SAHA was diluted with culture media. For in vivo assays, SAHA was diluted in 45% PEG 400 (Sigma) and 55% water.
Conditioning of Recipients and HCT.
Production of anti-CD3 mAb (145-2C11) was described in our previous publication (10) . Recipient mice were injected i.v. with anti-CD3 (5 g/g) on day Ϫ9 and were injected i.p. with SAHA (40 -200 g/g) 12 and 1 h before anti-CD3 injection, then SAHA was injected daily for 7 days after anti-CD3 injection. On day 0, the conditioned recipients were transplanted with donor BM cells (2 ϫ 10 6 /g, Ϸ50 ϫ 10 6 per mouse) and CD4 ϩ T-depleted spleen cells (4 ϫ 10 6 /g). The BM and spleen cells were injected again 7 days after the first injection. The recipients were monitored for clinical signs of GVHD and checked for chimerism as previously described (9 -11) . Proteinuria in NZB/W F1 mice was measured on a scale of 1-4ϩ using a colorimetric assay for albumin (Albustix, Bayer). Mice were considered to have proteinuria if three consecutive urine samples were Ͼ2ϩ, according to the scale (100 mg/dl), as described in our previous publications (29, 30) .
